atrasentan has been researched along with sirolimus in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | atrasentan (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, M; Börgermann, C; Hess, J; Rübben, H; Schenck, M; Vom Dorp, F | 1 |
1 other study(ies) available for atrasentan and sirolimus
| Article | Year |
|---|---|
[Value of targeted therapy for prostate cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Atrasentan; Calcitriol; Drug Delivery Systems; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrrolidines; Sirolimus; Survival Rate; Thionucleotides | 2008 |